Price$76.19+1.89 (+2.54%)
01:30 PM07:45 PM
News · 26 weeks65+183%
2026-01-182026-07-12
Mix3190d
- Insider15(48%)
- SEC Filings8(26%)
- Other6(19%)
- Earnings2(6%)
Latest news
25 items- INSIDERChief Executive Officer Quisel John D exercised 33,000 shares at a strike of $10.68 and sold $2,473,780 worth of shares (33,000 units at $74.96) as part of a pre-agreed trading plan (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- SECSEC Form 144 filed by Disc Medicine Inc.144 - Disc Medicine, Inc. (0001816736) (Subject)
- INSIDERChief Operating Officer Yu Jonathan Yen-Wen exercised 100 shares at a strike of $13.50 and sold $8,250 worth of shares (100 units at $82.50) as part of a pre-agreed trading plan (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERChief Legal Officer Khara Rahul exercised 2,500 shares at a strike of $14.69 and sold $187,500 worth of shares (2,500 units at $75.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERChief Operating Officer Yu Jonathan Yen-Wen sold $21,750 worth of shares (300 units at $72.50) as part of a pre-agreed trading plan and exercised 300 shares at a strike of $13.50 (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- SECDisc Medicine Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - Disc Medicine, Inc. (0001816736) (Filer)
- INSIDERChief Operating Officer Yu Jonathan Yen-Wen exercised 9,700 shares at a strike of $13.50 and sold $704,795 worth of shares (9,700 units at $72.66) as part of a pre-agreed trading plan (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- SECDisc Medicine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Disc Medicine, Inc. (0001816736) (Filer)
- INSIDERChief Legal Officer Khara Rahul exercised 7,500 shares at a strike of $14.69 and sold $526,661 worth of shares (7,500 units at $70.22) as part of a pre-agreed trading plan (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERChief Executive Officer Quisel John D exercised 34,000 shares at a strike of $9.86 and sold $2,387,296 worth of shares (34,000 units at $70.21) as part of a pre-agreed trading plan (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERSEC Form 4 filed by Director White William Richard4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERSEC Form 4 filed by Director Ratcliffe Liam4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERSEC Form 4 filed by Director Nicholson Donald William4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERSEC Form 4 filed by Director Gemayel Georges4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERSEC Form 4 filed by Director Chin Mark4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERSEC Form 4 filed by Director Bitterman Kevin4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERSEC Form 4 filed by Director Ahmed Nadim4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERChief Operating Officer Yu Jonathan Yen-Wen exercised 18,612 shares at a strike of $9.86 and sold $1,287,801 worth of shares (18,612 units at $69.19) as part of a pre-agreed trading plan (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- SECSEC Form 144 filed by Disc Medicine Inc.144 - Disc Medicine, Inc. (0001816736) (Subject)
- PRDisc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual MeetingData from the RALLY-MF trial of DISC-0974 in patients with myelofibrosis (MF) and anemia demonstrate meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status or concomitant JAK inhibitor useUpdated data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP) show sustained reductions in protoporphyrin IX (PPIX), significant improvement in light tolerance measures, and favorable longer-term safety Management will host a corporate update conference call on Monday, June 15 at 8:00 am ET WATERTOWN, Mass., June 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biop
- PRDisc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic ProtoporphyriaAligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submission by end of 2026 WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it has completed a Type A meeting with the US Food and Drug Administration (FDA) to discuss the Complete Response Letter (CRL) to the New Drug Application (NDA) for bitopertin in erythropoieti
- PRDisc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingDemonstrated meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response was seen independent of concomitant JAK inhibitor therapy use WATERTOWN, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presents updated data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF at the ASCO Annual Meeting in Chicago, IL. In this updated data set, treatment with DISC-0974 shows substantial reductions in hepci
- PRDisc Medicine Launches Expanded Access Program for Bitopertin for EPP PatientsThe expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decisionBitopertin, an oral glycine transporter 1 (GlyT1) inhibitor, is being evaluated in the Phase 3 APOLLO clinical trial, with topline data anticipated in Q4 2026 WATERTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the launch of an expanded access program (EAP) for bitopertin for eligible patient
- PRDisc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 CongressOral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemiaAdditional abstracts highlighting updates on HELIOS open label extension study of bitopertin in EPP, EPP LIGHT study (patient survey on life and health impact of disease), and DISC-3405 trial in progress for polycythemia veraManagement will host a corporate update conference call on Monday, June 15 at 8:00 am ET WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today a
- PRDisc Medicine to Participate in Upcoming Investor ConferencesWATERTOWN, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at two upcoming investor conferences: H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 19th at 4:30 p.m. ET.Jefferies Global Healthcare Conference on Wednesday, June 3rd at 3:10 p.m. ET. Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at ir.discmedicine.com
IRON FAQ
5 questionsWhere does IRON stock trade?
Disc Medicine Inc. (IRON) is listed on NASDAQ.What sector and industry is IRON in?
Disc Medicine Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about IRON?
Disc Medicine Inc. has had 8 recent analyst actions on file. The most recent action was from Stifel: Buy on 2025-11-03.What companies are similar to IRON?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IRON side-by-side with any of them on Quantisnow.How can I track IRON on Quantisnow?
Quantisnow aggregates Disc Medicine Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IRON to receive live email and push alerts on every new disclosure.